Semaglutide is a compounded prescription medication designed for long-term weight management when combined with a reduced-calorie diet and increased physical activity. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), mirrors the action of the natural GLP-1 hormone released in the gut after meals. Its application in weight loss functions as an appetite suppressant, prompting a sensation of fullness earlier during meals. This leads to reduced calorie intake and facilitates weight loss.
Semaglutide is given as a weekly self-injection underneath the skin which is discussed during your initial consultation. Dosing and treatment schedules are tailored to meet individual needs and weight loss objectives. Monthly adjustments to the dose are made based on individual progress. Typically, patients use Semaglutide for around five months or until their target weight is reached. Following weight achievement, patients may opt to continue with a maintenance dose or discontinue treatment altogether. If weight regain occurs after stopping treatment, Semaglutide can be reintroduced at any point.
With a proper diet, patients typically see a weight loss of 1-3 pounds per week, however, results differ depending on the individual.
$379/month
$279 per month for the first 3 months!
*Prices are subject to change depending on medication and supply costs*
Tirzepatide acts as a dual GLP-1 and GIP receptor agonist. It mimics the actions of two hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By activating GLP-1 receptors, tirzepatide stimulates insulin secretion in response to elevated blood sugar levels, while also slowing gastric emptying, which promotes a feeling of fullness and reduces food intake. Additionally, it inhibits glucagon release, further helping to lower blood sugar. The activation of GIP receptors enhances the release of insulin in response to food intake, complementing the effects of GLP-1. This dual action results in better blood sugar regulation and significant weight loss, as tirzepatide reduces appetite and slows digestion, leading to reduced calorie consumption. Because it targets both GLP-1 and GIP receptors, tirzepatide is thought to offer more effective glucose control and greater weight loss than Semalgutide and other GLP-1 medications.
Results will vary depending on each individual. In most cases, weight loss results begin withing 4-8 weeks. Weight loss tends to happen more gradually. More significant and sustained weight loss usually occurs over 3 to 6 months. In clinical studies, patients experienced ongoing weight loss over a longer duration, with peak results often seen after 6 months to 1 year of consistent use.
*Prices are subject to change depending on medication and supply costs*
Complete regular follow-ups with our provider to monitor progress, receive support and adjust dose.
The services provided have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. The material on this website is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any therapy program. Any designations or references to therapies are for marketing purposes only.